--- title: "TechPrecision | 10-K: FY2025 Revenue: USD 34.03 K" type: "news" locale: "en" url: "https://longbridge.com/en/news/250864249.md" published_at: "2025-07-30T21:30:47.000Z" --- # TechPrecision | 10-K: FY2025 Revenue: USD 34.03 K Revenue: As of FY2025, the actual value is USD 34.03 K. EPS: As of FY2025, the actual value is USD -0.29. EBIT: As of FY2025, the actual value is USD -2.158 K. ### Ranor Segment - **Revenue**: $18,165 thousand for the fiscal year ended March 31, 2025, an increase of 2% compared to $17,821 thousand in the previous year. - **Cost of Revenue**: $12,623 thousand, a decrease of 5% from $13,273 thousand in the previous year. - **Gross Profit**: $5,674 thousand, representing a 16% gross margin, up from 14% in the previous year. - **SG&A Expenses**: $2,545 thousand, a 13% increase from $2,260 thousand in the previous year. - **Operating Income**: $3,129 thousand, a 37% increase from $2,287 thousand in the previous year. ### Stadco Segment - **Revenue**: $15,998 thousand for the fiscal year ended March 31, 2025, an increase of 10% compared to $14,567 thousand in the previous year. - **Cost of Revenue**: $17,211 thousand, an increase of 15% from $14,997 thousand in the previous year. - **Gross Loss**: -$1,345 thousand, representing a -3% gross margin, down from -1% in the previous year. - **SG&A Expenses**: $3,298 thousand, a 6% increase from $3,125 thousand in the previous year. - **Operating Loss**: -$4,643 thousand, a 31% increase from -$3,554 thousand in the previous year. ### Consolidated Financials - **Consolidated Revenue**: $34,031 thousand, an 8% increase from $31,591 thousand in the previous year. - **Consolidated Cost of Revenue**: $29,702 thousand, an 8% increase from $27,473 thousand in the previous year. - **Consolidated Gross Profit**: $4,329 thousand, representing a 13% gross margin, consistent with the previous year. - **Consolidated SG&A Expenses**: $6,487 thousand, a 26% decrease from $8,750 thousand in the previous year, primarily due to the absence of due diligence work on the terminated Votaw acquisition. - **Consolidated Operating Loss**: -$2,158 thousand, a 53% improvement from -$4,632 thousand in the previous year. ### Cash Flow - **Operating Cash Flow**: -$599 thousand for the fiscal year ended March 31, 2025, compared to $728 thousand provided in the previous year. - **Investing Cash Flow**: -$1,081 thousand, compared to -$2,591 thousand in the previous year. - **Financing Cash Flow**: $1,737 thousand, compared to $1,467 thousand in the previous year. ### Outlook / Guidance - The company plans to closely monitor expenses and, if required, reduce operating costs and capital spending to enhance liquidity. There is substantial doubt about the company’s ability to continue as a going concern due to recurring operating losses at Stadco and the need for alternative financing. ### Related Stocks - [TPCS.US - TechPrecision](https://longbridge.com/en/quote/TPCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | TechPrecision|8-K:2026 财年 Q3 营收 7.09 百万美元 | | [Link](https://longbridge.com/en/news/276168955.md) | | 贝森特和沃什的 “导师”,德鲁肯米勒 Q4“精准” 开仓金融股 ETF、标普等权重 ETF 和巴西 ETF | 科技股方面,德鲁肯米勒 Q4 清仓了 Meta,加仓了谷歌与 Sea。德鲁肯米勒与贝森特、沃什的 “师徒” 关系让市场推测,“德鲁肯米勒经济学”——即反赤字、反通胀、反关税——可能通过贝森特和沃什渗透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) | | 摩尔线程快速完成对 Qwen3.5 模型全面适配 | 摩尔线程宣布已在旗舰级 AI 训推一体全功能 GPU MTT S5000 上完成对阿里最新大模型 Qwen3.5 的全方位适配。此次支持充分展示了摩尔线程 MUSA 生态的成熟度与完备性,开发者可通过 MUSA C 编程语言及 Triton | [Link](https://longbridge.com/en/news/276153560.md) | | 特斯拉首辆 Cybercab 下线:没有方向盘和踏板的汽车终于来了 | 特斯拉宣布,首辆赛博无人驾驶电动车 Tesla Cybercab 在美国得州超级工厂正式下线。风险提示及免责条款 市场有风险,投资需谨慎。本文不构成个人投资建议,也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、 | [Link](https://longbridge.com/en/news/276188665.md) | | 苹果加速研发 AI 眼镜、挂饰及摄像头版 AirPods | 作为向人工智能驱动硬件转型的一部分,苹果公司正加速开发三款新型可穿戴设备,包括智能眼镜、一款挂饰设备以及具备扩展 AI 功能的 AirPods。这些设备将围绕 Siri 数字助理构建,并依靠具备不同功能的摄像头系统,根据视觉语境执行操作。苹 | [Link](https://longbridge.com/en/news/276167877.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.